Basilea's Ceftobiprole Dubbed Qualified Infectious Disease Product

Basilea Pharmaceutica's ceftobiprole was designated by the FDA as a qualified infectious disease product – a status under which the drug is eligible for an additional five years of market exclusivity if approved for the indications.